Table 3.

Association between any or advanced adenomas and varying definitions of exposure according to the durations of observed insulin exposurea

Any adenomaAdvanced adenoma
Exposure definitions Duration of insulin exposureCaseControlCrude ORAdjusted ORbCaseControlCrude ORAdjusted ORb
No insulin141 (71.9)51 (77.0)ReferenceReference44 (74.6)51 (77.0)ReferenceReference
≥6 months49 (26%)144 (22%)1.2 (0.9–1.8)1.3 (0.9–1.8)14 (24%)144 (22%)1.1 (0.6–2.1)1.2 (0.6–2.2)
≥12 months41 (23%)124 (19%)1.2 (0.8–1.8)1.2 (0.8–1.8)10 (19%)124 (19%)0.9 (0.5–1.9)0.9 (0.5–2.0)
≥18 months40 (22%)92 (15%)1.6 (1.1–2.4)1.6 (1.1–2.5)9 (17%)92 (15%)1.2 (0.5–2.4)1.2 (0.6–2.5)
≥2 years34 (19%)77 (13%)1.6 (1.0–2.5)1.7 (1.1–2.6)8 (15%)77 (13%)1.2 (0.6–2.7)1.3 (0.6–2.9)
≥3 years23 (14%)43 (8%)2.0 (1.1–3.4)2.0 (1.2–3.4)6 (12%)43 (8%)1.6 (0.7–4.1)1.7 (0.7–4.3)
Each incremental year of insulin therapyn/an/a1.2 (1.0–1.3)1.2 (1.0–1.3)n/an/a1.0 (0.8–1.3)1.0 (0.8–1.3)
  • aCases and controls who had insulin exposure less than 6 months in duration were excluded from this analysis.

  • bAdjusted for sex and age only as none of the other variables met the a priori confounder selection criteria.